H.C. Wainwright downgraded Predictive Oncology (POAI) to Neutral from Buy without a price target after the company started working with a strategic advisor to evaluate various alternatives. The firm cites the strategic uncertainties and Predictive’s financial overhang for the downgrade.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks